TD Asset Management
ANTX icon

TD Asset Management’s AN2 Therapeutics ANTX Stock Holding History

TD Asset Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,800
Closed -$529K – 1386
2023
Q4 		$529K Buy
+25,800
New +$432K ﹤0.01% 1292

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TD Asset Management's ANTX Position: Q1 2024 in Review

TD Asset Management sold out of AN2 Therapeutics (ANTX) in Q1 2024, closing a stake of 25,800 shares — an estimated $529K sold.

TD Asset Management first reported a position in ANTX in Q4 2023 and held it in 1 quarter. The position peaked at $529K in Q4 2023. 54 funds tracked by Wall St. Rank hold ANTX as of Q1 2024.

  • TD Asset Management reported no remaining AN2 Therapeutics position as of Q1 2024 after selling out during the quarter.
  • TD Asset Management sold 25,800 AN2 Therapeutics shares in Q1 2024, an estimated $529K.
  • TD Asset Management first reported a position in AN2 Therapeutics in Q4 2023 and held it in 1 quarter.
  • TD Asset Management's AN2 Therapeutics position peaked at $529K in Q4 2023.
  • 54 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2024.

Based on TD Asset Management's 13F filing for Q1 2024, filed 8 May 2024.